Trimodality therapy (TMT), consisting of maximal transurethral resection of bladder tumor (TURBT) followed by concurrent chemoradiotherapy, has emerged as a bladder-sparing alternative to radical ...

At the 2025 UCSF-UCLA PSMA Conference, Matthias Eiber compares PSMA-617 and PSMA-I&T radiopharmaceuticals. He notes both agents share binding motifs but differ in chelator properties and linker ...

PDIGREE phase III adaptive, enrolled 1000+ metastatic kidney cancer patients across 500+ sites, ASCO 2025 results and innovative treatment strategies, PDIGREE Trial Tests Adaptive Immunotherapy ...

CONTACT-03 subset analysis, cabozantinib efficacy regardless of prior IO-IO or IO-TKI treatment, ASCO insights on kidney cancer sequencing, CONTACT-03 Subset Analysis: Similar Cabozantinib Response ...

February 19, 2025 Prostate specific membrane antigen (PSMA) PET scans recently gained approval from the United States FDA in 2020 for staging newly diagnosed prostate cancer. Given the increased ...

Zachary Klaassen hosts Alessandro Viti to discuss early oncological outcomes in very high-risk prostate cancer patients using PSMA-PET imaging. Dr. Viti addresses the research question of how surgery ...

Erectile Dysfunction - Read the latest Erectile Dysfunction research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

Penile Cancer - Read the latest Penile Cancer research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC CG Oncology, Inc.

ASCO 2025, bladder cancer, muscle-invasive bladder cancer (MIBC), SURE-01 trial, radical cystectomy, neoadjuvant sacituzumab govitecan (SG), monotherapy, sacituzumab govitecan followed by radical ...

SNMMI 2025 positive predictive value of 18F-piflufolastat PET/CT, prostate/prostatic bed, patients with biochemical recurrence when stratified by PSA level at the time of imaging, CONDOR study.